Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03223350 · ClinicalTrials.gov registry record · Phase 2
Topical Capsaicin for Cyclical Vomiting
A Phase 2 study, sponsored by Henry Ford Health System.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT03223350 is a Phase 2 study that has completed, run by Henry Ford Health System. The registered enrollment target is 30 participants.
The verdict
NCT03223350, a Phase 2 study, has completed, sponsored by Henry Ford Health System.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
This is a phase 2 randomized controlled trial testing the effect of topical capsaicin for the relieve of nausea and vomiting.
Interventions
- DRUG Placebos
- DRUG Capsaicin 0.1% Cream
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-12-20 |
| Est. Completion | 2019-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03223350
The ClinicalTrials.gov registry entry for NCT03223350 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT03223350 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03223350 about?
NCT03223350 is a clinical study titled "Topical Capsaicin for Cyclical Vomiting". This is a phase 2 randomized controlled trial testing the effect of topical capsaicin for the relieve of nausea and vomiting.
What is the current status of trial NCT03223350?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2017-12-20. Estimated completion is 2019-08-05.
What interventions are being tested in trial NCT03223350?
The interventions under investigation include: Placebos (DRUG), Capsaicin 0.1% Cream (DRUG).
Who is sponsoring clinical trial NCT03223350?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.